Abstract:Ubiquitin-specific protease 14 (USP14), one of three proteasome-associated deubiquitinating enzymes, has multifunctional roles in cellular context. Here, we report a novel molecular mechanism and function of USP14 in regulating autophagy induction and nuclear factor-kappa B (NF-κB) activation induced by toll-like receptor (TLR) 4 (TLR4). USP14 interacted with tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and interrupted the association of Beclin 1 with TRAF6, leading to inhibition of TRAF6-mediated ubiquitination of Beclin 1. Reduced expression of USP14 in USP14-knockdown (USP14KD) THP-1 cells enhanced autophagy induction upon TLR4 stimulation as shown by the increased conversion of cytosolic LC3-I to membrane-bound LC3-II. Moreover, USP14KD human breast carcinoma MDA-MB-231 cells and USP14KD human hepatic adenocarcinoma SK-HEP-1 cells showed increased cell migration and invasion, indicating that USP14 is negatively implicated in the cancer progression by the inhibition of autophagy induction. Furthermore, we found that USP14 interacted with TAK1-binding protein (TAB) 2 protein and induced deubiquitination of TAB 2, a key factor in the activation of NF-κB. Functionally, overexpression of USP14 suppressed TLR4-induced activation of NF-κB. In contrast, USP14KD THP-1 cells showed enhanced activation of NF-κB, NF-κB-dependent gene expression, and production of pro-inflammatory cytokines such as IL-6, IL-1β, and tumor necrosis factor-α. Taken together, our data demonstrate that USP14 can negatively regulate autophagy induction by inhibiting Beclin 1 ubiquitination, interrupting association between TRAF6 and Beclin 1, and affecting TLR4-induced activation of NF-κB through deubiquitination of TAB 2 protein.

Ubiquitin-Specific Protease 14 Negatively Regulates Toll-Like Receptor 4-Mediated Signaling and Autophagy Induction by Inhibiting Ubiquitination of TAK1-Binding Protein 2 and Beclin 1

Ubiquitin-Specific Protease 4 (Usp4) Targets Traf2 And Traf6 For Deubiquitination And Inhibits Tnf Alpha-Induced Cancer Cell Migration

Ubiquitin-specific protease 14 regulates LPS-induced inflammation by increasing ERK1/2 phosphorylation and NF-κB activation

Ubiquitin-specific Protease 14 is a New Therapeutic Target for the Treatment of Diseases.

USP4 targets TAK1 to downregulate TNF|[alpha]|-induced NF-|[kappa]|B activation

USP18 negatively regulates NF-κB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms

USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6.

Usp2a Negatively Regulates Il-1-And Virus-Induced Nf-B Activation By Deubiquitinating Traf6

USP 2 a negatively regulates IL-1 band virus-induced NFk B activation by deubiquitinating TRAF 6

Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3.

USP15 negatively regulates lung cancer progression through the TRAF6-BECN1 signaling axis for autophagy induction

USP19 Inhibits TNF-α– and IL-1β–Triggered NF-κB Activation by Deubiquitinating TAK1

The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-κB activation by dephosphorylating the protein kinase TAK1.

The Dual-Specificity Phosphatase Dusp14 Negatively Regulates Tumor Necrosis Factor- And Interleukin-1-Induced Nuclear Factor-Kappa B Activation By Dephosphorylating The Protein Kinase Tak1

USP14: Structure, Function, and Target Inhibition

Ubiquitin-specific Protease 4 Mitigates Toll-like/Interleukin-1 Receptor Signaling and Regulates Innate Immune Activation*

Regulation of TLR-triggered Innate Immune Response by Ubiquitin-Specific Protease 25 (180.8)

Regulation of T Cell Function by the Ubiquitin-Specific Protease USP9X Via Modulating the Carma1-Bcl10-Malt1 Complex.

USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex.

USP11 Negatively Regulates TNFα-induced NF-κB Activation by Targeting on IκBα

USP4 is regulated by Akt phosphorylation and deubiquitylates TGF-beta type I receptor